ARTICLE
Volume 10,Issue 7
17 July 2024
Research Progress on the Anti-Atherosclerotic Effect and Mechanism of Tetramethylpyrazine
Shengyang Gong ,
Zheng Cao
Show Less
1
Department of Cardiology, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, Hubei Province, China,
JCNR 2024 , 8(6), 94–99;
https://doi.org/10.26689/jcnr.v8i6.7032
© 2024 by the Authors. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract
Atherosclerosis is a chronic vascular disease and the most common pathological change of cardiovascular disease. Its pathogenesis is closely related to inflammation, oxidative stress, lipid accumulation, and calcinosis. Tetramethylpyrazine plays an anti-atherosclerotic role by regulating lipid metabolism, inhibiting foam cell formation, alleviating inflammation, inhibiting vascular calcification and abnormal platelet activation, and has a cardiovascular protective effect. Therefore, this paper summarized the research progress of the anti-atherosclerosis effect and mechanism of tetramethylpyrazine.
References
The Writing Committee of the Report on Cardiovascular Health Diseases in China, 2023, Interpretation of Report on Cardiovascular Health and Diseases in China 2022. Chinese Journal of Cardiovascular Medicine, 28(04): 297–312.
Libby P, Buring JE, Badimon L, et al., 2019, Atherosclerosis. Nat Rev Dis Primers, 5(1): 56.
Libby P, 2021, The Changing Landscape of Atherosclerosis. Nature, 592(7855): 524–533.
Lin J, Wang Q, Zhou S, et al., 2022, Tetramethylpyrazine: A Review on Its Mechanisms and Functions. Biomedicine and Pharmacotherapy, (150): 113005.
Xu P, Zhai Y, Wang J, 2018, The Role of PPAR and Its Cross-Talk with CAR and LXR in Obesity and Atherosclerosis. Int J Mol Sci, 19(4): 1260.
Fu R, Zhang Y, Guo Y, et al., 2014, Digital Gene Expression Analysis of the Pathogenesis and Therapeutic Mechanisms of Ligustrazine and Puerarin in Rat Atherosclerosis. Gene, 552(1): 75–80.
Zhang Y, Ren P, Kang Q, et al., 2017, Effect of Tetramethylpyrazine on Atherosclerosis and SCAP/SREBP-1c Signaling Pathway in ApoE-/- Mice Fed with a High-Fat Diet. Evidence-Based Complementary and Alternative Medicine, (2017): 1–8.
Brown MS, Radhakrishnan A, Goldstein JL, 2018, Retrospective on Cholesterol Homeostasis: The Central Role of Scap. Annual Review of Biochemistry, 87(1): 783–807.
Jiang F, Qian J, Chen S, et al., 2011, Ligustrazine Improves Atherosclerosis in Rat Via Attenuation of Oxidative Stress. Pharmaceutical biology, 49(8): 856–863.
Wang G, Shi C, Sun M, et al., 2013, Tetramethylpyrazine Attenuates Atherosclerosis Development and Protects Endothelial Cells from ox-LDL. Cardiovascular Drugs and Therapy, 27(3): 199–210.
Duan J, Xiang D, Luo H, et al., 2017, Tetramethylpyrazine Suppresses Lipid Accumulation in Macrophages Via Upregulation of the ATP-Binding Cassette Transporters and Downregulation of Scavenger Receptors. Oncol Rep, 38(4): 2267–2276.
Wolf D, Ley K, 2019, Immunity and Inflammation in Atherosclerosis. Circulation Research, 124(2): 315–327.
Falck-Hansen M, Kassiteridi C, Monaco C, 2013, Toll-Like Receptors in Atherosclerosis. International Journal of Molecular Sciences, 14(7): 14008–14023.
Li X, He J, Liu H, et al., 2009, Tetramethylpyrazine Suppresses Interleukin-8 Expression in LPS-Stimulated Human Umbilical Vein Endothelial Cell by Blocking ERK, p38 and Nuclear Factor-KappaB Signaling Pathways. Journal of Ethnopharmacology, 125(1): 83–89.
Chen J, Wang H, Gao C, et al., 2019, Tetramethylpyrazine Alleviates LPS-Induced Inflammatory Injury in HUVECs by Inhibiting Rho/ROCK Pathway. Biochemical and Biophysical Research Communications, 514(1): 329–335.
Chrissobolis S, Miller AA, Drummond GR, et al., 2011, Oxidative Stress and Endothelial Dysfunction in Cerebrovascular Disease. Front Biosci (Landmark Ed), 16(5): 1733–1745.
Forstermann U, Xia N, Li H, 2017, Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis. Circulation Research, 120(4): 713–735.
Li WM, Liu HT, Li XY, et al., 2010, The Effect of Tetramethylpyrazine on Hydrogen Peroxide-Induced Oxidative Damage in Human Umbilical Vein Endothelial Cells. Basic and Clinical Pharmacology and Toxicology, 106(1): 45–52.
Fan X, Wang E, He J, et al., 2019, Ligustrazine Protects Homocysteine-Induced Apoptosis in Human Umbilical Vein Endothelial Cells by Modulating Mitochondrial Dysfunction. J Cardiovasc Transl Res, 12(6): 591–599.
Ni X, Wong SL, Wong CM, et al., 2014, Tetramethylpyrazine Protects against Hydrogen Peroxide-Provoked Endothelial Dysfunction in Isolated Rat Aortic Rings: Implications for Antioxidant Therapy of Vascular Diseases. Evidence-Based Complementary and Alternative Medicine, (2014): 1–10.
Li H, Yang M, 2022, Ligustrazine Activates the PPAR-Gamma Pathway and Plays a Protective Role in Vascular Calcification. Vascular, 30(6): 1224–1231.
Camare C, Pucelle M, Negre-Salvayre A, et al., 2017, Angiogenesis in the Atherosclerotic Plaque. Redox Biol, (12): 18–34.
Wang L, Li G, Chen Q, et al., 2015, Octanoylated Ghrelin Attenuates Angiogenesis Induced by ox-LDL in Human Coronary Artery Endothelial Cells Via the GHSR1a-Mediated NF-KappaB Pathway. Metabolism, 64(10): 1262–1271.
Apte RS, Chen DS, Ferrara N, 2019, VEGF in Signaling and Disease: Beyond Discovery and Development. Cell, 176(6): 1248–1264.
Park JA, Kwon YG, 2018, Hippo-YAP/TAZ Signaling in Angiogenesis. BMB Rep, 51(3): 157–162.
Yuan R, Shi W, Xin Q, et al., 2018, Tetramethylpyrazine and Paeoniflorin Inhibit Oxidized LDL-Induced Angiogenesis in Human Umbilical Vein Endothelial Cells Via VEGF and Notch Pathways. Evidence-Based Complementary and Alternative Medicine, (2018): 1–12.
Zhu X, Shan Y, Yu M, et al., 2021, Tetramethylpyrazine Ameliorates Peritoneal Angiogenesis by Regulating VEGF/Hippo/YAP Signaling. Frontiers in Pharmacology, (12): 649581.
Sheu JR, Kan YC, Hung WC, et al., 1997, Mechanisms Involved in the Antiplatelet Activity of Tetramethylpyrazine in Human Platelets. Thromb Res, 88(3): 259–270.
Zhang Y, Ma XJ, Guo CY, et al., 2016, Pretreatment with a Combination of Ligustrazine and Berberine Improves Cardiac Function in Rats with Coronary Microembolization. Acta Pharmacol Sin, 37(4): 463–472.
Sheu JR, Kan YC, Hung WC, et al., 2000, The Antiplatelet Activity of Tetramethylpyrazine is Mediated Through Activation of NO Synthase. Life Sci, 67(8): 937–947.
Li L, Chen H, Shen A, et al., 2019, Ligustrazine Inhibits Platelet Activation Via Suppression of the Akt Pathway. Int J Mol Med, 43(1): 575–582.
Vinchi F, Porto G, Simmelbauer A, et al., 2020, Atherosclerosis is Aggravated by Iron Overload and Ameliorated by Dietary and Pharmacological Iron Restriction. European Heart Journal, 41(28): 2681–2695.
Zhou Q, Chen S, Li H, et al., 2020, Tetramethylpyrazine Alleviates Iron Overload Damage in Vascular Endothelium Via Upregulating DDAHII Expression. Toxicology in Vitro, (65): 104817.
Zhang M, Sun MY, Guo CY, et al., 2019, Effect of Tetramethylpyrazine and Hyperlipidemia on Hepcidin Homeostasis in Mice. Int J Mol Med, 43(1): 501–506.
Share
Back to top
Bio-Byword Scientific Publishing Pty. Ltd.
We are committed to supporting the scientific community by publishing impactful research and fostering effective communication among scientists. We continuously seek ways to accelerate scientific progress while upholding transparency and open dialogue. Our goal is to make knowledge freely and barrier‑free accessible to all.
Contact us: info@bbwpublisher.com
Level 10, 50 Clarence Street Sydney, NSW 2000 Australia